## EOD v3.3 Review and Conversion:
After EOD v3.3 has been deployed
1. Soft Tissue Other to Soft Tissue Rare: The following changes are necessary due to the conversion from Sex [220] to Sex Assigned at Birth [225]. This affects Schema ID [3800], AJCC ID [995] and potentially TNM Edition Number [1060] for cases starting as Soft Tissue Other.
- If Date of Diagnosis Year is 2018 or later and Schema ID [3800] = 00459 (Soft Tissue Other) and Primary Site [400] is C481, C482, C488 and Histology ICDO3 [522] = 8806, 8930, 8931
- Set Schema ID [3800] = 00450
- Set AJCC ID [995] = 45
- If TNM Edition Number [1060] is blank or 00 (indicating that TNM is NOT coded in the record), no additional changes are necessary.
- If TNM Edition Number [1060] is any value other than 00 or blank, set TNM Edition Number [1060] = 08
- No other changes are necessary, No manual review is necessary.
- (This can always be applied. Calculation tables were updated. No review necessary.)
2. Oropharynx to Nasopharynx: The following changes are necessary due to the adjustment in the assignment of Primary Site [400] = C111. This conversion affects Schema ID [3800], AJCC ID [995] and potentially TNM Edition Number [1060], Schema Discriminator 1 [3926], Schema Discriminator 2 [3927], SEER SSF1 [3700] for cases with Primary Site = C111. However manual review is also necessary for a number of other fields (detailed below).
- If Date of Diagnosis Year is 2025 or later and Primary Site [400] = C111 and Schema ID [3800] = 00100 or 00111
- Set Schema ID [3800] = 09090 (Nasopharynx V9)
- Set Schema Discriminator 1 [3926] to blank (not needed, all cases are Nasopharynx V9)
- Set Schema Discriminator 2 [3927] to blank (only defined for Oropharynx schemas)
- Set SEER_SSF1: SEER Site-Specific Fact 1 [3700] to blank (not defined for Nasopharynx)
- If Histology ICD-O-3 [522] = 8071-8072, 8083, 8260
- Set AJCC ID [995] = 9016
- If TNM Edition Number [1060] is blank or 00 (indicating that TNM is NOT coded in the record), no additional changes are necessary.
- If TNM Edition Number [1060] is any value other than 00 or blank, set TNM Edition Number [1060] = 09
- For all other histologies
- Set AJCC ID = XX
- Set TNM Edition Number = 88
- The case **will require manual review**: the following fields, if collected, will have to be reviewed.
- EOD 2018 Primary Tumor [772], EOD 2018 Regional Nodes [774], EOD 2018 Mets [776]
- Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clin [1068], Grade Post Therapy Path [3845]
- Summary Stage 2018 [764]
- AJCC TNM Clin T, N, M and Stage Group [1001, 1002, 1003, 1004]
- AJCC TNM Path T, N, M and Stage Group [1011, 1012, 1013, 1014]
- AJCC TNM Post Therapy Clin T, N, M and Stage Group [1062, 1064, 1066, 1067]
- AJCC TNM Post Therapy Path T, N, M and Stage Group [1021, 1022, 1023, 1024]
- Suggested message: "The Schema has changed from one of the Oropharynx to Nasopharynx. The EOD, Grade, Summary Stage, and AJCC field definitions differs and the case must be recoded."
3. Prostate Derived EOD 2018 Stage Group [818]: the derivation table has been updated for calculations involving Derived Summary Grade [1975] = 9, A-E or involving PSA Lab Value [3920] = XXX,2, XXX,3, XXX.7, XXX.9. If either field has such a value, the Derived EOD 2018 Stage Group should be recalculated. This affects Derived EOD 2018 Stage Group [818] for Prostate. Either approach shown below would address the issue.
If your registry captures/calculates Derived EOD 2018 fields:
- A) If Date of Diagnosis Year is 2018 or later and Schema ID [3800] = 00580
- Recalculate the Derived EOD 2018 Stage Group
- B) If Date of Diagnosis Year is 2018 or later and Schema ID [3800] = 00580 and Derived EOD 2018 Stage Group [818] = 1, 2A, 3A
- If Derived Summary Grade [1975] = 9, A, B, C, D, E or is blank,
- Set Derived EOD 2018 Stage Group = 99
- Else if PSA Lab Value [3920] = XXX.2, XXX.3, XXX.7, XXX.9
- Set Derived EOD 2018 Stage Group = 99
- No other changes are necessary. No manual review is necessary.
- (This can always be applied. Calculation tables were updated. No review necessary.)
## EOD v3.3 changes:
### EOD and SS2018
*- includes changes to schema definitions, EOD fields and SS2018*
- General Changes
- Version 9 Updated Diseases: AJCC released the 9th revision of the 2 diseases which will be effective for cases diagnosed 1/1/2026 or after. There are now 2 schemas for each. Also, the Oropharynx schemas were renamed to align with the new terminology.
- Major Salivary Glands [8th: 2018-2025], Schema ID [#3800] = 00080
- Major Salivary Glands [V9: 2026+], Schema ID [#3800] = 09081
- Oropharynx HPV-Associated [8th: 2018-2025], Schema ID [#3800] = 00100
- Oropharynx HPV-Associated [V9: 2026+], Schema ID [#3800] = 09100
- Sex Assigned At Birth [225]: Sex was used for the schema selection of Primary Peritoneal Carcinoma, Retroperitoneum, Soft Tissue Other, Soft Tissue Rare. NAACCR is discontinuing Sex [220] and adding Sex Assigned at Birth [225]. For additional details, see the schema notes below.
- Type of Reporting Source [500] was added as a field to all schema in preparation of more robust default value logic. Similar to Primary Site [400], this is solely to make the field available for calculations and no change in how it is collected or presented is necessary.
- Behavior ICDO3 [523] was added to all schemas that did not already have it where SS2018 = 0 (In situ) is valid in preparation of more robust default value logic
- RX Summ Surgery/Radiation Sequence [1380], RX Summ Systemic/Surgery Sequence [1639] were removed from all schema except Prostate, as they are not used in the calculations in EOD 2018.
- Derived EOD 2018 T, N, M and Stage Group fields [785, 815, 795, 818] will no longer be calculated or available in the public SEER EOD 2018 Staging tools. By agreement between NCI and AJCC, these fields are not supposed to be available or used in the facilities and are solely a central registry feature. If you are a vendor supporting a central registry that uses the Derived EOD 2018 fields, please let Nicki Schussler (schusslern@imsweb.com) know as soon as possible so the appropriate support can be provided.
- Appendix, Appendix V9
- EOD Regional Nodes [774]: Note 3 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Regional Nodes Positive [820]: Default set to 99 to align with all other schemas
- Bile Ducts Distal, Bile Ducts Perihilar, Cystic Duct, Gallbladder
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection.
- Breast
- EOD Primary Tumor [772]: Note 2 modified to indicate it relates to clinical evidence descriptions only. Code 450 is scheduled for removal, please use code 400 moving forward; Code 700 is scheduled for removal, please use code 600 moving forward. Codes 450 and 700 modified to indicate they are obsolete; there is no conversion at this time. Code 500 modified to specify WITHOUT inflammatory carcinoma and remove code 450
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Buccal Mucosa, Floor of Mouth, Gum, Lip, Mouth Other, Palate Hard, Tongue Anterior, Cutaneous Carcinoma of Head and Neck
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Colon and Rectum
- EOD Regional Nodes [774]: Note 3 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Esophagus, Esophagus Squamous
- EOD Regional Nodes [774]: Note 3 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- HemeRetic
- Summary Stage 2018 [764]: Code 1 and Code 7 modified to indicate the correct Note reference
- Hypopharynx, Larynx Glottic, Larynx Subglottic, Larynx Supraglottic, Larynx Other
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Lung
- EOD Primary Tumor [772]: Code 500 modified to add Azgos vein and Stellate ganglion and thoracic nerve roots and remove Brachial plexus inferior branches or NOS; Code 650 modified to remove Azygos vein and Stellate ganglion and to add Brachial vein, Supra-aortic arteries, Brachial plexus, Subclavian vessels and Thymus
- Major Salivary Glands 8th, Major Salivary Glands V9
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Maxillary Sinus, Nasal Cavity & Ethmoid Sinus
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Nasopharynx V9
- Schema Selection: for Date of Diagnosis Year 2025 and later, all Primary Site [400] = C111 with Histology ICD-O-3 [522] = 8000-8700 will be assigned to Nasopharynx, and Schema Discriminator 1 [3926] will no longer be associated with Nasopharynx V9. Schema Selection rules streamlined accordingly
- Schema Notes modified to include all C111 in this schema and remove references to Schema Discriminator 1 and Oropharynx schemas
- Schema Discriminator 1 [3926]: removed from the schema
- Nasopharynx 8th, Nasopharynx V9
- Summary Stage 2018 [764]: Notes introduction modified to show C111 logic differs in 2018-2024
- Oropharynx HPV-Mediated (p16+)
- Scheme renamed as 'Oropharynx HPV-Associated [8th: 2018-2025]'
- Schema Selection: for Date of Diagnosis Year 2025 and later, all Primary Site [400] = C111 with Histology ICD-O-3 [522] = 8000-8700 will be assigned to Nasopharynx, and Schema Discriminator 1 [3926] will only be applied to cancers with Date of Diagnosis Year 2024 and prior. All other selections are limited to 2018-2025 for the addition of the V9 schema. **(See 'EOD v3.3 Review and Conversion')**
- Schema Notes modified to reflect that C111 only is assigned to Oropharyx in 2018-2024; Schema Notes modified to reflect new names of Oropharynx schemas
- Oropharynx (p16-)
- Scheme renamed as 'Oropharynx HPV-Independent'
- Schema Selection: for Date of Diagnosis Year 2025 and later, all Primary Site [400] = C111 with Histology ICD-O-3 [522] = 8000-8700 will be assigned to Nasopharynx, and Schema Discriminator 1 [3926] will only be applied to cancers with Date of Diagnosis Year 2024 and prior. **(See 'EOD v3.3 Review and Conversion')**
- Schema Notes modified to reflect that C111 only is assigned to Oropharyx in 2018-2024; Schema Notes modified to reflect new names of Oropharynx schemas
- Oropharynx HPV-Associated 8th, HPV-Associated V9, Oropharynx HPV-Independent
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Summary Stage 2018 [764]: Notes introduction modified to show C111 logic only applies to 2018-2024
- Pancreas, Stomach
- EOD Regional Nodes [774]: Note 4 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Primary Peritoneal Carcinoma, Retroperitoneum
- Schema Selection: NAACCR is discontinuing Sex [220] and adding Sex Assigned at Birth [225]. Schema selection for Primary Peritoneal Carcinoma modified to include Sex Assigned at Birth = 2 and Schema selection for Retroperitoneum modified to include Sex Assigned at Birth = 1, 9
- Small Intestine
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
- Soft Tissue Other, Soft Tissue Rare
- Schema Selection: NAACCR is discontinuing Sex [220] and adding Sex Assigned at Birth [225]. While the previous definition of Sex, if Sex = 4 for C481-C482, C488 with 8806, 8930-8931, the cancer was assigned to Soft Tissue Other. These patients will now have Sex Assigned at Birth = 9 and will be assigned to Soft Tissue Rare. **(See 'EOD v3.3 Review and Conversion')**
- Testis
- EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
**SSDI and Grade**
*- NAACCR is the custodian of these fields, changes are listed here for convenience. See Change Log on [https://apps.naaccr.org/ssdi/list/]([https://apps.naaccr.org/ssdi/list/]) for complete information.*
- Bile Duct Intrahepatic, Liver
- Fibrosis Score [3835]: added an end year for the SEER RC collection as SEER is no longer collecting these fields
- Bone Appendicular Skeleton, Bone Pelvis, Bone Spine
- Percent Necrosis Post Neoadjuvant [3908]: added end year of 2025 as this is no longer required by any standard setter
- Breast
- HER2 Overall Summary [3255]: Note 7 modified to streamline the instructions
- Residual Cancer Burden [1178]: added as a new SSDI; required by CoC and SEER (RC) for 2026 forward
- Residual Cancer Burden Class [1179]: added as a new SSDI; required by CoC and SEER (RC) for 2026 forward
- Multigene Signature Method [3894], Multigene Signature Result [3895]: added an end year for the SEER RC collection as SEER is no longer collecting these fields
- Oncotype DX Risk Level DCIS [3905], Oncotype DX Risk Level Invasive [3906]: added end year of 2025 as this is no longer required by any standard setter
- Oncotype DX Recurence Score-DCIS [3903]: added end year to SEER (RC), this is no longer required by SEER
- Buccal Mucosa and all Head & Neck
- Extranodal Extension Head and Neck Clinical [3831], Extranodal Extension Head and Neck Pathological [3832]: To streamline both maintenance and the manual, these schemas will all use the same two validation table and notes for these SSDIs. Additional Information text was modified for both Source Documents and Other Names
- Extranodal Extension Head and Neck Clinical [3831]: Note 2 modified to include additional information about sources and indications of ENE; Coding Guidelines 1-4 modified for readability; Coding Guideline 6 for Code 9 final bullet removed – LN biopsy performed and is negative for ENE or not state; Code 1 modified for readability
- Extranodal Extension Head and Neck Pathological [3832]: Note 2 modified to include additional information about sources and indications of ENE; Note 3 added, this was split from Note 2 for regional vs distant; Note 4 added to clarify minor vs major ENE; Coding Guidelines 9 first bullet modified to move the explanation into Note 2; changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Buccal Mucosa and all H&N, Cutaneous Carcinoma of Head and Neck
- LN Size [3883]: To streamline both maintenance and the manual, these schemas will all use the same validation table and notes for this SSDI. Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck Code 0 for LN Size will thus contain 'Non-invasive neoplasm (behavior /2)'; Note 2 added to describe the criteria for coding LN Size; Note 3 modified to add more clarity on the use of clinical or pathological size; Coding Guidelines 1 modified to specify the size is in millimeters
- Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck, Melanoma Head and Neck
- LN Head and Neck Levels I-III [3876], LN Head and Neck Levels IV-V [3877], LN Head and Neck Levels IV-VII [3878], LN Head and Neck Other [3879]: To streamline both maintenance and the manual, both schema will use the same validation table and notes for these SSDIs. Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck code 0 for these fields will thus contain 'Non-invasive neoplasm (behavior /2)' ; changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck
- Schema Discriminator 1 [3926]: Notes and code meanings were adjusted for the Nasopharynx V9 schema and the Oropharynx schemas name change and V9 addition
- Cervix 8th, Cervix V9, Cervix Sarcoma, Corpus Adenosarcoma, Corpus Carcinoma & Carcinosarcoma, Corpus Sarcoma, Fallopian Tube, Ovary, Placenta, Primary Peritoneal Carcinoma, Vagina, Vulva 8th, Vulva V9
- FIGO Stage [3836]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Cervix 8th, Cervix V9, Vagina, Vulva 8th, Vulva V9
- LN Status: Pelvic [3957]: Coding Guidelines 1.c. modified to replace 'femoral-inguinal' replaced with 'pelvic' both times it appeared; SEER requirement corrected to be SEER (RC)
- Cervix 8th, Cervix V9, Vagina
- LN Status: Para-aortic [3958]: Coding Guidelines 1.c. modified to replace 'femoral-inguinal' replaced with 'para-aortic' both times it appeared; SEER requirement corrected to be SEER (RC)
- Colon and Rectum
- Tumor Deposits [3934]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Corpus Carcinoma and Carcinosarcoma
- Microsatellite Instability (MSI) [3890]: added as a new SSDI for this schema; required by CoC and SEER (RC) for 2026 forward
- Cutaneous Carcinoma of Head and Neck
- High Risk Histologic Features [3858]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- GIST
- KIT Gene Immunohistochemistry [3865]: added Note 2 describing the types of results that can be used to code field.
- Heart, Mediastinum, and Pleura; Retroperitoneum; Soft Tissues Abdomen and Thoracic; Soft Tissues Head and Neck; Soft Tissues Trunk and Extremeties; Soft Tissue Rare; Soft Tissue Other
- Bone Invasion [3815]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- HemeRetic
- JAK2 [3862]: Additional Information modified to limit the Source Documents to clinical lab tests.
- Kidney Parenchyma
- Ipsilateral Adrenal Gland Involvement[3861], Invasion Beyond Capsule [3864], Major Vein Involvement [3886]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Lacrimal Gland
- Adenoid Cystic Basaloid Pattern [3803]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Lung V9
- Spread Through Air Spaces (STAS) [1176]: added as a new SSDI; required by CoC and SEER (RC) for 2026 forward
- PD-L1 [1174]: Note 5 was added to describe the limited way in which Combined Proportion Score can be used
- Lung 8th, Lung V9
- Separate Tumor Nodules [3929], Visceral and Parietal Pleural Invasion [3937]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Lymphoma; Lymphoma CLL/SLL
- B Symptoms [3812], NCCN International Prognostic Index (IPI) [3896]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Melanoma Choroid and Ciliary Body; Melanoma Iris
- Chromosome 3 Status [3821], Chromosome 8q Status [3822], Extravascular Matrix Pattern [3834], Microvascular Density [3891]: added end year to SEER (RC), this is no longer required by SEER
- Melanoma Skin
- Clinical Width Margin [3961]: Note 1 modified to specify field is for C44x cancers only and all others should use XX.9; changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- LDH Lab Value [3932]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Merkel Cell Skin
- LN Isolated Tumor Cells (ITC) [3880], Profound Immune Suppression [3918]: changed SEER requirement to SEER (RC) for 2018 forward, these are now only required by SEER if the cancer is reported by a CoC facility
- Nasopharynx [8th: 2018-2024], Oropharynx HPV-Associated [8th: 2018-2025], Oropharynx HPV-Independent
- Schema Discriminator 1 [3926]: Notes modified to reflect the new names for the Oropharynx schemas and to limit this discriminator to diagnosis years 2018-2024; Validation table modified to remove Nasopharynx V9 as the discriminator is not needed for that schema, and that the Discriminator should be blank for 2025 and later
- Schema Discriminator 2 [3927]: Description modified to include the new names for the Oropharynx schemas; additional information is provided regarding how to determine HPV status; Notes modified to reflect the new names for the Oropharynx schemas; Note 2 modified to expand what types of test can be considered and to specify how different results scenarios should be coded; Validation table modified to adjust the Oropharynx schema names and IDs
- NET Schemas
- Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clin [1068], Grade Post Therapy Path [3845]: Note 4/5 modified to add explanation of when codes A-D can be used; Note 5/6 added to specify terminology that cannot be used to code Grade; Note 6/7 added to describe what information can be used to code grade, starting with physician’s statement.
- Plasma Cell Myeloma
- High-risk Cytogenetics [3857]: Note 2 added to indicate this SSDI is a component of R-ISS and how to code if only R-ISS stage is given
- LDH Level [3869]: Note 3 modified to indicate this SSDI is a component of R-ISS and how to code if only R-ISS stage is given
- Serum Albumin Pretreatment Level [3930]: Additional Information Source Documents modified to provide a more complete list of sources; Note 2 sub-bullet modified to specify which test results can be used; Note 3 sub-bullet added to describe how to code if only R-ISS stage is given
- Serum Beta-2 Microglobulin Pretreatment Level [3931]: Note 3 modified to indicate this SSDI is a component of R-ISS and how to code if only R-ISS stage is given
- Prostate
- PSA Lab Value [3920]: Note 3 added to specify how performance diagnostic biopsy affection collection of PSA Lab Value with examples as this is a change in the rules; Coding Guidelines 1 sub-bullets removed as they are covered by Note 3
- Number of Cores Positive [3898], Number of Cores Examined [3897]: Note 4 added to define how to code targeted or region of interest biopsies
- Vagina, Vulva 8th, Vulva V9
- LN Status: Femoral-Inguinal [3959]: SEER requirement corrected to be SEER (RC)
- LN Laterality [3881]: added end year to SEER requirement, this is no longer required by SEER